Although aminoglycosides have demonstrated translational readthrough in vitro and been confirmed in preliminary proof-of-concept studies in humans20,21,55, neither amikacin nor gentamicin rescues enough CFTR function to reach the therapeutic threshold necessary to impart long-term clinical benefits for CF. The gene discussed is CFTR; the disease is cystic fibrosis.